Clinical Trial Protocol
Iranian Registry of Clinical Trials

04 Aug 2026

Assessing the clinical effects of a short-term course of Oral Furosemide in postpartum period in patients with preeclampsia during pregnancy : A Randomized Controlled Trial

Protocol summary

Study aim
Examining the prevalence of persistent hypertension on the 5th day after delivery or the day the patients were discharged from the hospital (whichever occurred earlier)

Design
A controlled, parallel-group, single-blind, randomized, phase 3 clinical trial in 118 patients. The rand function of Excel software was used for randomization.

Settings and conduct
The study was conducted in an academic hospital affiliated to Iran University of Medical Sciences. Blinding was performed on the patients. Patients will be randomized and one group will be prescribed only angiotensin inhibitor drugs and the other group will be prescribed furosemide drugs in addition to this drug. The groups will then be compared with each other in terms of specified clinical outcomes

Participants/Inclusion and exclusion criteria
Inclusion criteria: All patients with recent pregnancy which was complicated with preeclampsia. patients under 18 and those with renal disease or history of hypertension or history of congenital heart defects will be excluded

Intervention groups
Women with recent pregnancy who had high blood pressure during pregnancy. In the intervention group, in addition to the usual treatment, which includes the administration of angiotensin receptor blockers, low-dose furosemide is prescribed. In the control group, only angiotensin receptor blocking drugs will be prescribed

Main outcome variables
Prevalence of persistent hypertension in day 5 post partum

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20230722058884N1**
Registration date: **2023-11-30, 1402/09/09**
Registration timing: **registered_while_recruiting**

Last update: **2023-11-30, 1402/09/09**
Update count: **0**

Registration date
2023-11-30, 1402/09/09

Registrant information

Name
Maliheh Fakehi

Name of organization / entity

Country
Iran (Islamic Republic of)

Phone
+98 21 5560 6034

Email address
maryam.fakehi@gmail.com

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2023-09-23, 1402/07/01

Expected recruitment end date
2024-03-19, 1402/12/29

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Assessing the clinical effects of a short-term course of

Oral Furosemide in postpartum period in patients with preeclampsia during pregnancy : A Randomized Controlled Trial

Public title
Effect of Oral Furosemide on patients with preeclampsia during pregnancy
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
All patients who have had a recent pregnancy with preeclampsia
Exclusion criteria:
Age under 18 Patients with prior history of hypertension Patients with renal disease Patients with history of congenital heart defects
Age
From **18 years** old
Gender
Female

Phase
3
Groups that have been masked

- Participant

Sample size
Target sample size: **118**
Randomization (investigator's opinion)
Randomized
Randomization description
The randomization protocol for this clinical trial is designed to ensure the unbiased allocation of participants into different treatment groups. Prior to the start of the trial, a computer-generated randomization list will be created by an independent statistician who is not involved in the recruitment or allocation process. Using this list, participants will be assigned to one of two treatment arms in a random manner. The randomization process will not be stratified The allocation sequence will be concealed from the researchers, participants, and study personnel until the intervention is assigned. This rigorous randomization process reduces the likelihood of selection bias, increases internal validity, and allows for a more accurate assessment of the treatment effects in the subsequent analysis.
Blinding (investigator's opinion)
Single blinded
Blinding description
In this study only the patients will be blinded.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Iran University if Medical Sciences
Street address
Beside Milad Tower, Hemmat highway,
City
Tehran
Province
Tehran
Postal code
۱۴۴۹۶۱۴۵۳۵
Approval date
2022-07-13, 1401/04/22
Ethics committee reference number
IR.IUMS.FMD.REC.1401.224

Health conditions studied

1

Description of health condition studied
Unspecified pre-eclampsia
ICD-10 code
O14.9
ICD-10 code description
Unspecified pre-eclampsia

Primary outcomes

1

Description
Prevalence of persistent hypertension in day 5 post partum
Timepoint
Day 5 post partum
Method of measurement
Manual sphygmomanometer

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Patients with preeclampsia who are treated with ARB plus low does Furosemide
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Shahid Akbarabadi Hospital

Full name of responsible person
Parisa Hajari

Street address
Beside Molavi Subway Station, Molavi Street

City
Tehran

Province
Tehran

Postal code
1168743514

Phone
+98 21 5560 6034

Email
parisa.hajari72@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Kazem Mousavizadeh

Street address
Beside Milad Tower, Hemmat Highway

City
Tehran

Province
Tehran

Postal code
۱۴۴۹۶۱۴۵۳۵

Phone
+98 21 86710

Email
mousavizadeh.k@iums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Iran University of Medical Sciences

Proportion provided by this source
100

Public or private sector
Public

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Parisa Hajari

Position
Resident

Latest degree
Medical doctor

Other areas of specialty/work
Gynecology and Obstetrics

Street address
No.57, Shahrivar Avenue, North Karegar Street

City
Tehran

Province
Tehran

Postal code
1457713611

Phone
+98 21 6604 4657

Email
parisa.hajari72@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Parisa Hajari

Position
Resident

Latest degree
Medical doctor

Other areas of specialty/work
Gynecology and Obstetrics

Street address
No 57, Shahrivar Street, North Karegar Aveneu

City
Tehran

Province
Tehran

Postal code
1457713611

Phone
+98 21 6604 4657

Email
parisa.hajari72@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Parisa Hajari

Position
Resident

Latest degree
Medical doctor
Other areas of specialty/work
Gynecology and Obstetrics
Street address
No 57, Shahrivar Street, North Karegar Avenue
City
Tehran
Province
Tehran
Postal code
1457713611
Phone
+98 21 6604 4657
Email
parisa.hajari72@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available